

# Curriculum Vitae

---

Jeffrey Cannon Cilley, MD

January 2021

## **MEDICAL EDUCATION:**

08/1996 to 05/2000 **Graduate: Doctor of Medicine**

Georgetown University School of Medicine

Washington, DC

08/1991 to 12/1995 **Undergraduate: Bachelor of Science in Psychology and Biochemistry**

Magna Cum Laude

University of Arizona

Tucson, AZ

## **POSTGRADUATE MEDICAL EDUCATION:**

07/2004 to 06/2007 **Fellowship: Hematology / Medical Oncology**

McGaw Medical Center of Northwestern University

Chicago, IL

07/2003 to 06/2004 **Chief Medical Resident: Northwestern Memorial Hospital**

McGaw Medical Center of Northwestern University

Chicago, IL

07/2000 to 06/2003 **Residency: Internal Medicine**

McGaw Medical Center of Northwestern University

Chicago, IL

### **BOARD CERTIFICATION:**

12/2007 (r2017)      **Hematology-** The American Board of Internal Medicine  
12/2007 (r2017)      **Medical Oncology-** The American Board of Internal Medicine  
08/2004                **Internal Medicine-** The American Board of Internal Medicine

### **HOSPITAL APPOINTMENTS:**

2007                    Northwestern Memorial Hospital, Chicago, IL  
2008                    Swedish Covenant Hospital, Chicago, IL  
2014                    St Francis Hospital, Evanston , IL  
2021                    NorthShore University Health System, Chicago, IL

### **FACULTY APPOINTMENTS/ PROJECTS**

07/2007 to 11/2012    Clinical Instructor of Medicine at Northwestern University School of  
Medicine, Chicago, IL  
12/2012 to Present    Assistant Professor of Medicine at Rush Medical College, Chicago, IL  
12/2012 to 2017        Rush Cancer Center Liaison at Swedish Covenant Hospital  
01/2013 to 01/2017    Chairman, Internal Review Board at Swedish Covenant Hospital  
01/2013 to Present    Medical Director, Infusion Center, Swedish Covenant Hospital  
10/2014 to Present    Medical Director, Integrated Cancer Care Program at Swedish Covenant  
Hospital, Chicago, IL (Grant Award- \$200K, Coleman Foundation)  
10/2014 to 10/2018    Principal Investigator, Lung Cancer Detection Initiative at Swedish Covenant  
Hospital  
01/2015 to 12/2015    Design Team Member for the Coleman Supportive Oncology Initiative,  
Distress Screening, Chicago, IL  
02/2015 to 02/2016    Fellow, Palliative Medicine Training Program, Coleman Foundation,  
Chicago, IL  
10/17/ 2015            Co-Chairperson, Swedish Covenant Hospital Gala, Chicago, IL, Raised over  
\$830K to enhance cancer services at SCH

01/2017 to 01/2021 Vice President Medical Staff, Swedish Covenant Hospital

07/2019 to Present Section Head, Hematology/ Oncology, Swedish Covenant Hospital

01/2021 to Present Medical Director, Niles Infusion Center, Swedish Hospital Part of NorthShore

01/2021 to Present President, Medical Staff, Swedish Hospital Part of NorthShore

## **PUBLICATIONS:**

- 1.) **Cilley J**, Rihn C, Monreal J, Gordon LI, Sighal s, Tallman M, Williams S, Winter J, Mehta J. *Ideal or actual body weight to calculate CD34+ cell doses for allogeneic hematopoietic stem cell transplantation?* Bone Marrow Transplant. 2004 Jan; 33(2):161-4.
- 2.) Rihn C, **Cilley J**, Nail P, Pedicano AV, Mehta J. *Definition of myeloid engraftment after allogeneic hematopoietic stem cell transplantation*. Haematologica. 2004 Jun; 89(6):763-4.
- 3.) **Cilley J**, Winter J. *Radioimmunotherapy and autologous stem cell transplantation for the treatment of B-cell lymphomas*. Haematologica. 2006 Jan; 91(1):113-20.
- 4.) **Cilley J**, Mulcahy M. *Adjuvant therapy for colon cancer*. Current Oncology Reports. 2006 May; 8(3):161-6.
- 5.) Evens AM, **Cilley J**, Ortiz T, Gounder M, Hou N, Rademaker A, Miyata S, Catsaros K, Augustyniak C, Bennett CL, Tallman MS, Variakojis D, Winter JN, Gordon LI. *G-CSF is not necessary to maintain over 99% dose-intensity with ABVD in the treatment of Hodgkin lymphoma: low toxicity and excellent outcomes in a 10-year analysis*. British Journal of Haematology. 2007 Jun; 137(6):545-52.
- 6.) Robin J, Fintel B, Pikovskaya O, Davidson C, **Cilley J**, Flaherty J. *Multiple myeloma presenting with high-output heart failure and improving with anti-angiogenesis therapy: two case reports and a review of the literature*. Journal of Medical Case Reports. July 2008 ;2(1): 229-6.
- 7.) **Cilley J**, Barfi K, Benson A, Mulcahy M. *Bevacizumab in the treatment of colorectal cancer*. Expert Opinion Biologic Therapy. May 2007 ;7(5): 739-749.
- 8.) Inwards D, **Cilley J**, Winter J. *Radioimmunotherapeutic strategies in autologous hematopoietic stem-cell transplantation for malignant lymphoma*. Best Practice and Research Clinical Haematology. Dec 2006; 19(4): 669-84.
- 9.) **Cilley J**, Winter J. *A phase I/II Trial of combined weekly bortezomib and Y-90-ibritumomab tiuxetan (zevalin) in patients with relapsed or refractory follicular lymphoma*. Lurie Comprehensive Cancer Center and Northwestern University Clinical Research Trial. 2007.